Designing glucokinase activators with reduced hypoglycemia risk: discovery of N,N-dimethyl-5-(2-methyl-6-((5-methylpyrazin-2-yl)-carbamoyl)benzofuran-4-yloxy)pyrimidine-2-carboxamide as a clinical candidate for the treatment of type 2 diabetes mellitus
✍ Scribed by Pfefferkorn, Jeffrey A.; Guzman-Perez, Angel; Oates, Peter J.; Litchfield, John; Aspnes, Gary; Basak, Arindrajit; Benbow, John; Berliner, Martin A.; Bian, Jianwei; Choi, Chulho; Freeman-Cook, Kevin; Corbett, Jeffrey W.; Didiuk, Mary; Dunetz, Joshua R.; Filipski, Kevin J.; Hungerford, William M.; Jones, Christopher S.; Karki, Kapil; Ling, Anthony; Li, Jian-Cheng; Patel, Leena; Perreault, Christian; Risley, Hud; Saenz, James; Song, Wei; Tu, Meihua; Aiello, Robert; Atkinson, Karen; Barucci, Nicole; Beebe, David; Bourassa, Patricia; Bourbounais, Francis; Brodeur, Anne M.; Burbey, Rena; Chen, Jing; D'Aquila, Theresa; Derksen, David R.; Haddish-Berhane, Nahor; Huang, Cong; Landro, James; Lee Lapworth, Amanda; MacDougall, Margit; Perregaux, David; Pettersen, John; Robertson, Alan; Tan, Beijing; Treadway, Judith L.; Liu, Shenping; Qiu, Xiayang; Knafels, John; Ammirati, Mark; Song, Xi; DaSilva-Jardine, Paul; Liras, Spiros; Sweet, Laurel; Rolph, Timothy P.
- Book ID
- 126035733
- Publisher
- The Royal Society of Chemistry
- Year
- 2011
- Tongue
- English
- Weight
- 652 KB
- Volume
- 2
- Category
- Article
- ISSN
- 2040-2503
No coin nor oath required. For personal study only.